Physiological promoters reduce the genotoxic risk of integrating gene vectors. - Test2 - elhamkhani - TriplyDB

Physiological promoters reduce the genotoxic risk of integrating gene vectors.

Physiological promoters reduce the genotoxic risk of integrating gene vectors.

http://www.wikidata.org/entity/Q40003414

about

Lentiviral vector gene therapy: effective and safe?Current and future alternative therapies for beta-thalassemia major Towards in vivo amplification: Overcoming hurdles in the use of hematopoietic stem cells in transplantation and gene therapy Foamy virus vectors for HIV gene therapy Gene therapy on the move Brief reports: Lysosomal cross-correction by hematopoietic stem cell-derived macrophages via tunneling nanotubes Retroviral vectors and transposons for stable gene therapy: advances, current challenges and perspectives Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1 Uncovering and dissecting the genotoxicity of self-inactivating lentiviral vectors in vivo Gene Therapy for X-Linked Severe Combined Immunodeficiency: Where Do We Stand?A self-inactivating gamma-retroviral vector reduces manifestations of mucopolysaccharidosis I in mice Omega-1 knockdown in Schistosoma mansoni eggs by lentivirus transduction reduces granuloma size in vivo Gene therapy of MPL deficiency: challenging balance between leukemia and pancytopenia.Wiskott-Aldrich syndrome: a comprehensive review.Incorporating double copies of a chromatin insulator into lentiviral vectors results in less viral integrants The 3' region of the chicken hypersensitive site-4 insulator has properties similar to its core and is required for full insulator activity.Stem cell marking with promotor-deprived self-inactivating retroviral vectors does not lead to induced clonal imbalance.Self-inactivating retroviral vector-mediated gene transfer induces oncogene activation and immortalization of primary murine bone marrow cells.Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors.Genotoxic potential of lineage-specific lentivirus vectors carrying the beta-globin locus control region.Cell-intrinsic and vector-related properties cooperate to determine the incidence and consequences of insertional mutagenesis.Update on gene therapy for immunodeficiencies.Cocal-pseudotyped lentiviral vectors resist inactivation by human serum and efficiently transduce primate hematopoietic repopulating cells.Neonatal intravenous injection of a gammaretroviral vector has a low incidence of tumor induction in mice.A self-inactivating lentiviral vector for SCID-X1 gene therapy that does not activate LMO2 expression in human T cells.Use of the piggyBac transposon to create stable packaging cell lines for the production of clinical-grade self-inactivating γ-retroviral vectors.Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing.Gene therapy strategies: can we eradicate HIV?Scale-up and manufacturing of clinical-grade self-inactivating γ-retroviral vectors by transient transfection Gammaretroviral vectors: biology, technology and application Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy.LDLR-Gene therapy for familial hypercholesterolaemia: problems, progress, and perspectives Deletion of the LTR enhancer/promoter has no impact on the integration profile of MLV vectors in human hematopoietic progenitors.Tracking of specific integrant clones in dogs treated with foamy virus vectors.Therapeutic levels of fetal hemoglobin in erythroid progeny of β-thalassemic CD34+ cells after lentiviral vector-mediated gene transfer.A modified γ-retrovirus vector for X-linked severe combined immunodeficiency.Treatment of canine leukocyte adhesion deficiency by foamy virus vectors expressing CD18 from a PGK promoter.Identification and characterization of enhancer-blocking insulators to reduce retroviral vector genotoxicity Gene therapy for canine leukocyte adhesion deficiency with lentiviral vectors using the murine stem cell virus and human phosphoglycerate kinase promoters.Contributions of gene marking to cell and gene therapies.

P2860

Q24630888-086204EA-8050-4764-ACCF-0C3E87C60953 Q26750906-A0B5185F-F04F-4934-A495-C2BEAD92F915 Q26771159-AE8C79FA-B6A9-4836-B2C0-23E51907E723 Q26859020-727A8699-B29E-49EC-89F7-72C36EEFD1FA Q27007012-A4EE8F46-7A0E-4581-A015-9662DC4C6E08 Q27330049-4706A0FA-E0D7-42E5-AA32-CA11AE6F4886 Q28074002-BCDC8FFD-F8AA-4AA3-8AA9-C527B4BEAAFA Q28290118-26ABA4DF-0042-49FF-A44E-865DF91E32BE Q28383769-525EF85B-E86C-4B02-B07D-5FEE48DEE264 Q30364488-F73F8B9E-A9EB-42B1-AF11-3960A798DA20 Q30493690-4A8DEA31-A957-4EE5-89DC-588E51613E79 Q30601730-98AA9F44-9B6A-40DD-9F52-EACBD5D1D4E8 Q33386724-41A31A9C-9B8C-4741-8EA4-AE308627F448 Q33406620-97F127E2-F42E-47F0-9650-99DE9F541BE7 Q33412009-52EB1B95-5746-4D8D-8AAB-6BA67B756D98 Q33502223-582DCC6A-F09F-4771-9D3B-BFEEA64074C2 Q33712953-9C8B8A5C-76E1-422E-B0BA-F9CB598EDAFA Q33713150-49D24216-7CDB-4097-868C-28BDDACF1988 Q33713156-33625FA1-FA0D-4422-A780-08BAA97DDBA1 Q33713196-793DA0B9-05EF-4769-98CB-03214CE5ED08 Q33713961-09AD2F6A-3958-47D3-B5B4-D6343877F143 Q33798427-585ECFA6-1A03-47E2-8D2B-F6B93D3E418D Q33822226-8AA9BF8D-4BCA-418A-8629-D0E6A5309149 Q33936562-E1A2AF51-12EC-4254-B1C1-9B4442F8434C Q34074917-403BBECB-5C8F-4CD6-A4AA-722E07F67D59 Q34082215-2F7B52C6-0D46-4C25-B381-3A22616D7E75 Q34160912-B1FA7767-37FC-4F63-8281-4BEA505B481F Q34165454-DD4B5D94-E0E3-4DFF-A18D-64512FF8D1B3 Q34204409-F724566B-9DE1-455D-8EA9-0715E69C77C1 Q34223822-9B530D17-A6C7-4CFD-9DD0-B767ACB5D019 Q34356914-3E134C7F-6703-4D26-9F42-4CD83DD538A3 Q34467839-A0D3A99A-29CC-4442-8AFB-9055DB2E9DC5 Q34576925-5FA5118B-6EEB-4538-84A9-7E94642DE1AE Q34589239-1A9732E2-788B-43FA-803A-B53C0DE60E92 Q34707143-67FAD2F5-1672-4B96-BA58-AAF46875A2E8 Q34763502-7A24220B-5067-4D43-8182-12EBF82B2E76 Q34819562-9DF0F438-5AD1-4374-9827-3872C6B6A96C Q35009501-47DD97BD-E131-4210-B3EF-FA6347EE150D Q35022870-64429245-6C64-4518-A45C-53A9DC90C548 Q35059829-960ADDE2-C0F1-416C-A00C-C83CB109ECAC

P2860

Physiological promoters reduce the genotoxic risk of integrating gene vectors.

http://www.wikidata.org/entity/Q40003414

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh

2008年學術文章

@zh-hant

name

Physiological promoters reduce the genotoxic risk of integrating gene vectors.

@en

type

label

Physiological promoters reduce the genotoxic risk of integrating gene vectors.

@en

prefLabel

Physiological promoters reduce the genotoxic risk of integrating gene vectors.

@en

P1433

Q40003414-ECE77696-3E4B-4053-9E90-5BE4C4CDAF1F

P1476

Q40003414-14EFD5B3-D6E9-4027-B691-66EA6A55279D

P2093

Q40003414-2654B9FF-2338-4700-AC27-89B8D2E9CFBC

Q40003414-350E469B-2C09-4F62-B69C-D9D732BA50D0

Q40003414-56458569-4C5D-4D07-A00E-8677421F1F0B

Q40003414-5AF6B4E2-4122-4086-B070-4DB357636AC5

Q40003414-5FA966B2-5F93-485C-9EC9-AFD3926FAE9A

Q40003414-A07A96A1-335E-4C7F-81F4-514A266D0928

Q40003414-BEFED2CF-0975-4522-AA6B-B63FACE36A3B

P304

Q40003414-7577EA75-9629-4FBE-92D6-ED8710D8437E

P31

Q40003414-BE30A0A2-BE2E-441E-B678-8C6ED6A268B7

P356

Q40003414-B93E8DCC-71AF-4ACF-A5BC-4FE05ED0E959

P433

Q40003414-3CE3D7DB-9998-465C-9279-E0E5A7FD8BFF

P478

Q40003414-C97B08B4-ACE3-4149-B4A9-9FAE6083A50E

P50

Q40003414-A5C70698-54A9-4EE3-92DC-85EEC90784E4

Q40003414-E669E89B-A18B-4DB6-839F-A565C3C8DEDD

P577

Q40003414-C85CFE09-4429-434E-916A-D728581056EB

P698

Q40003414-D3F3C59B-F5CE-443D-8789-B587D88E8802

P356

P1433

Molecular Therapy

P1476

Physiological promoters reduce the genotoxic risk of integrating gene vectors.

@en

P2093

Anjali Mishra

http://www.w3.org/2001/XMLSchema#string

Christopher Baum

http://www.w3.org/2001/XMLSchema#string

Daniela Zychlinski

http://www.w3.org/2001/XMLSchema#string

Elke Grassman

http://www.w3.org/2001/XMLSchema#string

Johann Meyer

http://www.w3.org/2001/XMLSchema#string

Tobias Maetzig

http://www.w3.org/2001/XMLSchema#string

Ute Modlich

http://www.w3.org/2001/XMLSchema#string

P304

718-725

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MT.2008.5

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P50

Daniela Zychlinski

P577

2008-03-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18334985

http://www.w3.org/2001/XMLSchema#string